SRRK vs. TARS, ADAP, AUTL, VIR, FDMT, BCRX, IMTX, KYTX, ADMA, and RGNX
Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Tarsus Pharmaceuticals (TARS), Adaptimmune Therapeutics (ADAP), Autolus Therapeutics (AUTL), Vir Biotechnology (VIR), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Immatics (IMTX), Kyverna Therapeutics (KYTX), ADMA Biologics (ADMA), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.
Scholar Rock (NASDAQ:SRRK) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
Tarsus Pharmaceuticals' return on equity of -74.28% beat Scholar Rock's return on equity.
Scholar Rock currently has a consensus price target of $25.17, suggesting a potential upside of 69.02%. Tarsus Pharmaceuticals has a consensus price target of $48.38, suggesting a potential upside of 50.61%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Tarsus Pharmaceuticals.
Scholar Rock has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.
91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 26.2% of Scholar Rock shares are held by insiders. Comparatively, 11.5% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Scholar Rock received 107 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 62.93% of users gave Scholar Rock an outperform vote while only 62.90% of users gave Tarsus Pharmaceuticals an outperform vote.
In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Scholar Rock. MarketBeat recorded 6 mentions for Tarsus Pharmaceuticals and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.36 beat Tarsus Pharmaceuticals' score of 0.41 indicating that Scholar Rock is being referred to more favorably in the media.
Tarsus Pharmaceuticals has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Scholar Rock beats Tarsus Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Scholar Rock News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scholar Rock Competitors List
Related Companies and Tools
